A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
Brief description of study
The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to patients with HER2-positive metastatic breast cancer. T-DXd is a treatment for cancer that targets specific cancer cells and delivers the anti-cancer drug directly to them. The study drug T-DXd received accelerated approval by the FDA in 2019.
Clinical Study Identifier: s20-00976
ClinicalTrials.gov Identifier: NCT04538742
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
